Cytotoxic T-lymphocyte-associated protein 4-Ig effectively controls immune activation and inflammatory disease in a novel murine model of leaky severe combined immunodeficiency
leaky-SCID; Treg; Artemis; immune dysregulation; regulatory T cell; cytotoxic T-lymphocyte-associated protein 4; Leaky severe combined immunodeficiency; CTLA4
Abstract :
[en] BACKGROUND: Severe combined immunodeficiency can be caused by loss-of-function mutations in genes involved in the DNA recombination machinery, such as recombination-activating gene 1 (RAG1), RAG2, or DNA cross-link repair 1C (DCLRE1C). Defective DNA recombination causes a developmental block in T and B cells, resulting in high susceptibility to infections. Hypomorphic mutations in the same genes can also give rise to a partial loss of T cells in a spectrum including leaky severe combined immunodeficiency (LS) and Omenn syndrome (OS). These patients not only experience life-threatening infections because of immunodeficiency but also experience inflammatory/autoimmune conditions caused by the presence of autoreactive T cells. OBJECTIVE: We sought to develop a preclinical model that fully recapitulates the symptoms of patients with LS/OS, including a model for testing therapeutic intervention. METHODS: We generated a novel mutant mouse (Dclre1cleaky) that develops a LS phenotype. Mice were monitored for diseases, and immune phenotype and immune function were evaluated by using flow cytometry, ELISA, and histology. RESULTS: Dclre1cleaky mice present with a complete blockade of B-cell differentiation, with a leaky block in T-cell differentiation resulting in an oligoclonal T-cell receptor repertoire and enhanced cytokine secretion. Dclre1cleaky mice also had inflammatory symptoms, including wasting, dermatitis, colitis, hypereosinophilia, and high IgE levels. Development of a preclinical murine model for LS allowed testing of potential treatment, with administration of cytotoxic T-lymphocyte-associated protein 4-Ig reducing disease symptoms and immunologic disturbance, resulting in increased survival. CONCLUSION: These data suggest that cytotoxic T-lymphocyte-associated protein 4-Ig should be evaluated as a potential treatment of inflammatory symptoms in patients with LS and those with OS.
Cytotoxic T-lymphocyte-associated protein 4-Ig effectively controls immune activation and inflammatory disease in a novel murine model of leaky severe combined immunodeficiency
Publication date :
November 2017
Journal title :
Journal of Allergy and Clinical Immunology
ISSN :
0091-6749
eISSN :
1097-6825
Publisher :
Mosby, St Louis, United States - Missouri
Volume :
140
Issue :
5
Pages :
1394-1403.e8
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Copyright (c) 2017 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Le Deist, F., Poinsignon, C., Moshous, D., Fischer, A., de Villartay, J.-P., Artemis sheds new light on V(D)J recombination. Immunol Rev 200 (2004), 142–155.
Shearer, W.T., Dunn, E., Notarangelo, L.D., Dvorak, C.C., Puck, J.M., Logan, B.R., et al. Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. J Allergy Clin Immunol 133 (2014), 1092–1098.
Moshous, D., Pannetier, C., Chasseval, Rd Rd, Deist, Fl Fl, Cavazzana-Calvo, M., Romana, S., et al. Partial T and B lymphocyte immunodeficiency and predisposition to lymphoma in patients with hypomorphic mutations in Artemis. J Clin Invest 111 (2003), 381–387.
Felgentreff, K., Lee, Y.N., Frugoni, F., Du, L., van der Burg, M., Giliani, S., et al. Functional analysis of naturally occurring DCLRE1C mutations and correlation with the clinical phenotype of ARTEMIS deficiency. J Allergy Clin Immunol 136 (2015), 140–150.e7.
Ege, M., Ma, Y., Manfras, B., Kalwak, K., Lu, H., Lieber, M.R., et al. Omenn syndrome due to ARTEMIS mutations. Blood 105 (2005), 4179–4186.
Liston, A., Enders, A., Siggs, O.M., Unravelling the association of partial T-cell immunodeficiency and immune dysregulation. Nat Rev Immunol 8 (2008), 545–558.
Fontenot, J.D., Rasmussen, J.P., Williams, L.M., Dooley, J.L., Farr, A.G., Rudensky, A.Y., Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22 (2005), 329–341.
Rooney, S., Sekiguchi, J., Zhu, C., Cheng, H.L., Manis, J., Whitlow, S., et al. Leaky Scid phenotype associated with defective V(D)J coding end processing in artemis-deficient mice. Mol Cell 10 (2002), 1379–1390.
Barthels, C., Puchałka, J., Racek, T., Klein, C., Brocker, T., Novel spontaneous deletion of artemis exons 10 and 11 in mice leads to T- and B-cell deficiency. PLoS One, 8, 2013, e74838.
Huang, Y., Giblin, W., Kubec, M., Westfield, G., St Charles, J., Chadde, L., et al. Impact of a hypomorphic Artemis disease allele on lymphocyte development, DNA end processing, and genome stability. J Exp Med 206 (2009), 893–908.
Li, L., Salido, E., Zhou, Y., Yannone, S.M., Dunn, E., Feeney, A.J., et al. Targeted disruption of the Artemis murine counterpart results in SICD and defective V(D)J recombination that is partially corrected with bone marrow transplantation. J Immunol 174 (2005), 2420–2428.
Jacobs, C., Huang, Y., Masud, T., Lu, W., Westfield, G., Giblin, W., et al. A hypomorphic Artemis human disease allele causes aberrant chromosomal rearrangements and tumorigenesis. Hum Mol Genet 20 (2011), 806–819.
Villa, A., Notarangelo, L.D., Roifman, C.M., Omenn syndrome: inflammation in leaky severe combined immunodeficiency. J Allergy Clin Immunol 122 (2008), 1082–1086.
Tian, L., Altin, J.A., Makaroff, L.E., Franckaert, D., Cook, M.C., Goodnow, C.C., et al. Foxp3+ regulatory T cells exert asymmetric control over murine helper responses by inducing Th2 cell apoptosis. Blood 118 (2011), 1845–1853.
Shi, Y., Radvanyi, L.G., Sharma, A., Shaw, P., Green, D.R., Miller, R.G., et al. CD28-mediated signaling in vivo prevents activation-induced apoptosis in the thymus and alters peripheral lymphocyte homeostasis. J Immunol 155 (1995), 1829–1837.
Tang, Q., Henriksen, K.J., Boden, E.K., Tooley, A.J., Ye, J., Subudhi, S.K., et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 171 (2003), 3348–3352.
Franckaert, D., Dooley, J., Roos, E., Floess, S., Huehn, J., Luche, H., et al. Promiscuous Foxp3-cre activity reveals a differential requirement for CD28 in Foxp3+ and Foxp3− T cells. Immunol Cell Biol 93 (2015), 417–423.
Milner, J.D., Fasth, A., Etzioni, A., Autoimmunity in severe combined immunodeficiency (SCID): lessons from patients and experimental models. J Clin Immunol 28:suppl 1 (2008), S29–S33.
Hsieh, C.-S., Lee, H.-M., Lio, C.-W.J., Selection of regulatory T cells in the thymus. Nat Rev Immunol, 12, 2012, 157.
Seidel, M.G., Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment. Blood 124 (2014), 2337–2345.
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322 (2008), 271–275.
Khiong, K., Murakami, M., Kitabayashi, C., Ueda, N., Sawa, S., Sakamoto, A., et al. Homeostatically proliferating CD4 T cells are involved in the pathogenesis of an Omenn syndrome murine model. J Clin Invest 117 (2007), 1270–1281.
Sandborn, W.J., Colombel, J., Sands, B.E., Rutgeerts, P., Targan, S.R., Panaccione, R., et al. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology 143 (2012), 62–69.e4.
